Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer

Shinichi Yamashita; Yoshimi Suzukamo; Kenichi Kakimoto; Motohide Uemura; Takeshi Kishida; Koji Kawai; Terukazu Nakamura; Takayuki Goto; Takahiro Osawa; Shigeyuki Yamada; Kazuo Nishimura; Norio Nonomura; Hiroyuki Nishiyama; Takumi Shiraishi; Osamu Ukimura; Osamu Ogawa; Nobuo Shinohara; Akihiro Ito; Yoichi Arai

doi:10.1111/iju.14422

Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer

Shinichi Yamashita, Yoshimi Suzukamo, Kenichi Kakimoto, Motohide Uemura, Takeshi Kishida, Koji Kawai, Terukazu Nakamura, Takayuki Goto, Takahiro Osawa, Shigeyuki Yamada, Kazuo Nishimura, Norio Nonomura, Hiroyuki Nishiyama, Takumi Shiraishi, Osamu Ukimura, Osamu Ogawa, Nobuo Shinohara, Akihiro Ito, Yoichi Arai

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Objective: To validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 in Japanese-speaking testicular cancer survivors. Methods: A total of 200 testicular cancer survivors were recruited at eight high-volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test–retest reliability, internal consistency and concurrent validity were evaluated. Results: The mean age at response was 43 years (range 22–74 years), and the mean period after treatment was 77 months (range 0–416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test–retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70–0.86). For internal consistency, four of seven scales met the criteria (Cronbach’s alpha 0.62–0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. The sex-related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains. Conclusions: The psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 questionnaire is a useful tool to assess the health-related quality of life of testicular cancer patients.

Original language	English
Pages (from-to)	176-182
Number of pages	7
Journal	International Journal of Urology
Volume	28
Issue number	2
DOIs	https://doi.org/10.1111/iju.14422
Publication status	Published - 2021 Feb

Keywords

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26
quality of life
survivor
testicular cancer
validation study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/iju.14422

Cite this

Yamashita, S., Suzukamo, Y., Kakimoto, K., Uemura, M., Kishida, T., Kawai, K., Nakamura, T., Goto, T., Osawa, T., Yamada, S., Nishimura, K., Nonomura, N., Nishiyama, H., Shiraishi, T., Ukimura, O., Ogawa, O., Shinohara, N., Ito, A., & Arai, Y. (2021). Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer. International Journal of Urology, 28(2), 176-182. https://doi.org/10.1111/iju.14422

@article{ea304a4fe7f545f0bf44b2c6a96219ee,

title = "Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer",

abstract = "Objective: To validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 in Japanese-speaking testicular cancer survivors. Methods: A total of 200 testicular cancer survivors were recruited at eight high-volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test–retest reliability, internal consistency and concurrent validity were evaluated. Results: The mean age at response was 43 years (range 22–74 years), and the mean period after treatment was 77 months (range 0–416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test–retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70–0.86). For internal consistency, four of seven scales met the criteria (Cronbach{\textquoteright}s alpha 0.62–0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. The sex-related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains. Conclusions: The psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 questionnaire is a useful tool to assess the health-related quality of life of testicular cancer patients.",

keywords = "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, quality of life, survivor, testicular cancer, validation study",

author = "Shinichi Yamashita and Yoshimi Suzukamo and Kenichi Kakimoto and Motohide Uemura and Takeshi Kishida and Koji Kawai and Terukazu Nakamura and Takayuki Goto and Takahiro Osawa and Shigeyuki Yamada and Kazuo Nishimura and Norio Nonomura and Hiroyuki Nishiyama and Takumi Shiraishi and Osamu Ukimura and Osamu Ogawa and Nobuo Shinohara and Akihiro Ito and Yoichi Arai",

note = "Funding Information: This work was supported in part by Grants‐in‐Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection. Funding Information: This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection. Publisher Copyright: {\textcopyright} 2020 The Japanese Urological Association",

year = "2021",

month = feb,

doi = "10.1111/iju.14422",

language = "English",

volume = "28",

pages = "176--182",

journal = "International Journal of Urology",

issn = "0919-8172",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Yamashita, S , Suzukamo, Y, Kakimoto, K, Uemura, M, Kishida, T, Kawai, K, Nakamura, T, Goto, T, Osawa, T, Yamada, S, Nishimura, K, Nonomura, N, Nishiyama, H, Shiraishi, T, Ukimura, O, Ogawa, O, Shinohara, N, Ito, A & Arai, Y 2021, 'Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer', International Journal of Urology, vol. 28, no. 2, pp. 176-182. https://doi.org/10.1111/iju.14422

Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer. / Yamashita, Shinichi ; Suzukamo, Yoshimi; Kakimoto, Kenichi et al.
In: International Journal of Urology, Vol. 28, No. 2, 02.2021, p. 176-182.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer

AU - Yamashita, Shinichi

AU - Suzukamo, Yoshimi

AU - Kakimoto, Kenichi

AU - Uemura, Motohide

AU - Kishida, Takeshi

AU - Kawai, Koji

AU - Nakamura, Terukazu

AU - Goto, Takayuki

AU - Osawa, Takahiro

AU - Yamada, Shigeyuki

AU - Nishimura, Kazuo

AU - Nonomura, Norio

AU - Nishiyama, Hiroyuki

AU - Shiraishi, Takumi

AU - Ukimura, Osamu

AU - Ogawa, Osamu

AU - Shinohara, Nobuo

AU - Ito, Akihiro

AU - Arai, Yoichi

N1 - Funding Information: This work was supported in part by Grants‐in‐Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection. Funding Information: This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18K09185). The authors thank Juntaro Koyama, Shinji Fujii, Takuma Sato, Shuichi Shimada, Yoshihide Kawasaki, Naoki Kawamorita and Koji Mitsuzuka (Tohoku University Graduate School of Medicine) for their assistance in data collection. Publisher Copyright: © 2020 The Japanese Urological Association

PY - 2021/2

Y1 - 2021/2

N2 - Objective: To validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 in Japanese-speaking testicular cancer survivors. Methods: A total of 200 testicular cancer survivors were recruited at eight high-volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test–retest reliability, internal consistency and concurrent validity were evaluated. Results: The mean age at response was 43 years (range 22–74 years), and the mean period after treatment was 77 months (range 0–416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test–retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70–0.86). For internal consistency, four of seven scales met the criteria (Cronbach’s alpha 0.62–0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. The sex-related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains. Conclusions: The psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 questionnaire is a useful tool to assess the health-related quality of life of testicular cancer patients.

AB - Objective: To validate the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 in Japanese-speaking testicular cancer survivors. Methods: A total of 200 testicular cancer survivors were recruited at eight high-volume institutions in Japan. The participants completed the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and the International Index of Erectile Function 15 questionnaires. A total of 40 participants completed a retest of the questionnaires 2 weeks after the first response. The psychometric properties of the Japanese version including test–retest reliability, internal consistency and concurrent validity were evaluated. Results: The mean age at response was 43 years (range 22–74 years), and the mean period after treatment was 77 months (range 0–416 months). The response rate for each item, except sexual function, was high, and the percentage of missing values was less than 3.5%. For test–retest reliability, seven of 12 scales met the criteria (intraclass correlation 0.70–0.86). For internal consistency, four of seven scales met the criteria (Cronbach’s alpha 0.62–0.91). For concurrent validity, treatment side effects of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were related to some domains of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. The sex-related subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 were moderately correlated with some International Index of Erectile Function 15 domains. Conclusions: The psychometric properties of the Japanese version are equivalent to the properties of the original European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26. The Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 questionnaire is a useful tool to assess the health-related quality of life of testicular cancer patients.

KW - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26

KW - quality of life

KW - survivor

KW - testicular cancer

KW - validation study

UR - http://www.scopus.com/inward/record.url?scp=85096827291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096827291&partnerID=8YFLogxK

U2 - 10.1111/iju.14422

DO - 10.1111/iju.14422

M3 - Article

C2 - 33174259

AN - SCOPUS:85096827291

SN - 0919-8172

VL - 28

SP - 176

EP - 182

JO - International Journal of Urology

JF - International Journal of Urology

IS - 2

ER -

Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this